by Brandon M Menachem  , Sandrine Hanna  , Deepika Kulkarni  and Hakim Azfar Ali

Received: 08 June 2023;  Published: 21 November 2023;  doi: 10.21926/obm.transplant.2304202

Treatment options for end stage lung diseases are limited to stabilizing lung failure, decreasing disease progression, and symptom management, but significant reversal of lost lung function is often not possible. For well selected patients, lung transplantation may be a viable option to improve both longevity and quality of life. Though outcomes for lung transplant recipients have improved over several decades, long term survival still lags behind that of other solid organ transplant recipients. Longevity after lun [...]

by Mostafa T. Mohammed  , Esmat Al Sharkawy  , Amel M. Kamal Eldin  , Emad Allam  , Manal M. Saber  , Anthony Nassar  , Nour Younis  , Christa Deban  , Ahmad Jaser  , Indira Guleria  , Basset El Essawy  , Anil Chandraker  , Mahmoud Nasr  and Jamil R. Azzi

Received: 15 March 2023;  Published: 06 November 2023;  doi: 10.21926/obm.transplant.2304201

Human leukocyte antigens (HLA) are unique proteins expressed on the surface of human cells, playing a pivotal role in the immune system, particularly in the contexts of infection, cancer, and transplantation. The widespread adoption of HLA typing methods has become an essential component in assessing donor-recipient compatibility, a crucial limiting factor in solid organ transplantation. In general, the greater the disparity between a donor's and recipient's HLA types, the higher the likelihood of provoking an allo [...]

by Biagio Pinchera  , Rosa Carrano  , Emilia Trucillo  , Alessia D'Agostino  , Alessia Sardanelli  , Simona Mercinelli  , Fabrizio Salemi  , Amerigo Piccione  , Elisa Schettino  , Paolo Romano  , Gianluca Rompianesi  , Roberto Ivan Troisi  and Ivan Gentile

Received: 19 July 2023;  Published: 01 November 2023;  doi: 10.21926/obm.transplant.2304200

The rising prevalence of MDR pathogens has a significant impact on the recipients' outcome, as this increases the risk of graft complications and makes the management of the peri-transplant phase more difficult. Among the different MDR germs, Methicillin-resistant Staphylococcus aureus (MRSA) represents one of the most frequently isolated pathogens. We report for the first time the off-label use of Ceftaroline in six kidney transplant recipients with donor peritransplantation MRSA bacteremia at the Division of Kidn [...]

by Aml Labib  , Jitesh Jeswani  and Durga AK Kanigicherla

Received: 26 June 2023;  Published: 13 October 2023;  doi: 10.21926/obm.transplant.2304199

IgAN is a major cause of end-stage kidney disease (ESKD) leading to kidney transplantation in a significant proportion of patients. However, its recurrence in transplanted kidneys can lead to graft loss. The rate of graft loss attributable to IgAN after transplantation is variably reported in different retrospective cohorts. Previous reports describe recurrence rates of 22-58% with a 1.3% to 16% rate of graft loss. Accurate diagnosis and prediction of graft loss are important for planning effective therapies to imp [...]

by Niccolò Castellani Nicolini  , Jacopo Belfiore  and Giandomenico Biancofiore

Received: 14 May 2023;  Published: 13 October 2023;  doi: 10.21926/obm.transplant.2304198

Liver transplantation (LT) is a life-saving treatment representing the only viable option for patients suffering from end-stage liver disease (ESLD) or acute liver failure. Patients who undergo LT require a multidisciplinary approach to postoperative pain management. However, pain management in this context is often inadequately explored. Limited options exist for proper pain control in patients with hepatic failure, mainly due to the increased risk of kidney and multi-organ failure. In LT candidates, specific anal [...]

by Christopher Thomas  , Matthias Williams  and Oksana A. Shlobin

Received: 07 August 2023;  Published: 11 October 2023;  doi: 10.21926/obm.transplant.2304197

Lung transplantation is a last-resort treatment option for patients with end stage lung disease. The procedure is being performed more frequently and scientific advances continue to be made, but the median post-transplant survival is far shorter than other solid organ transplant recipients. Candidate selection is a resource intensive process that attempts to balance risks of the procedure with the benefits of much higher quality of life. Transplant centers must weigh disease specific considerations, medical comorbi [...]

by Somaye-Sadat Heidari  , Nooshin Dalili  , Shiva Samavat  , Shiva Kalantari  , Leonard Foster  , Kyung-Mee Moon  and Mohsen Nafar

Received: 12 July 2023;  Published: 25 September 2023;  doi: 10.21926/obm.transplant.2303196

Acute antibody-mediated rejection (AMR) is a severe complication affecting kidney allografts' long-term survival. Timely detection and appropriate treatment of AMR are crucial for improving graft outcomes. This study aimed to discover non-invasive urinary biomarkers that can predict the response to therapy in patients with AMR. Materials and Methods: In this case-control study, urine samples from 21 biopsy-proven AMR patients underwent proteomics using label-free quantification. The patients were divided into two g [...]

by Rimmel Yosra Kanoun  , Nour Ben Abdeljelil  , Roua Hsasna  , Rabeb Jaied  , Sabrine Mekni  , Siwar Frigui  , Lamia Torjemane  , Dorra Belloumi  , Ines Turki  , Rihab Ouerghi  , Insaf Ben yaiche  , Wafa Achour  , Saloua Ladeb  and Tarek Ben Othman

Received: 12 April 2023;  Published: 12 September 2023;  doi: 10.21926/obm.transplant.2303195

Cytomegalovirus (CMV) infection is a common and severe complication following allogeneic stem cell transplantation (ASCT) and requires effective preemptive antiviral therapy. Both oral and intravenous (IV) antiviral agents effectively reduce CMV viral load and achieve viral clearance. Studies comparing oral and IV anti-CMV preemptive treatment in ASCT patients with CMV reactivation showed a potential difference in treatment response and safety profiles between the two administration routes. We retrospectively compa [...]

by Paayal Naidu  , William Sandawana Majoni  , Toby Coates  and Manohar Mogulla

Received: 11 May 2023;  Published: 04 September 2023;  doi: 10.21926/obm.transplant.2303194

Thrombotic microangiopathy (TMA) in kidney transplant recipients is uncommon and difficult to manage, often with poor graft outcomes [1]. This is a complex and interesting case of an older, highly sensitised kidney transplant recipient who presented with de novo post-transplant TMA in the setting of antibody mediated rejection (ABMR), with other drivers being tacrolimus toxicity, cytomegalovirus (CMV) infection and anti-SARS-CoV-2 BNT162b2 mRNA vaccination. This led to rapid, irrecoverable graft loss. 76-year-old f [...]

by Domingo J. Franco-Palacios  , Lisa Allenspach  , Lisa Stagner  , Kelly Bryce  , Jane Simanovski  and Hassan Nemeh

Received: 01 May 2023;  Published: 17 July 2023;  doi: 10.21926/obm.transplant.2303193

In the United States of America, COVID-19 acute respiratory distress syndrome (ARDS) and post-COVID pulmonary fibrosis (PCPF) are raising indications for lung transplant (LT). Another indication for LT is underlying fibrosis with SARS-CoV-2 induced interstitial lung disease exacerbation or rapid progressing fibrosis. Only a few centers have reported on their long-term outcomes after LT for COVID-19. Single center retrospective chart review of patients transplanted for COVID-19 related lung disease. The Henry Ford H [...]